Latest News
Keep up to date with all our latest investments, service offerings and news items.
-
-
May 17, 2023
Almac Diagnostic Services updates claraᵀ report with significant new content for cancer research
-
August 11, 2022
Almac, AstraZeneca CDx Partnership Branching Out to New Disease Areas, Drawing on NGS, qPCR
-
June 23, 2022
Almac Diagnostic Services collaborates with AstraZeneca to Develop and Commercialise Companion Diagnostics (CDx)
-
December 8, 2021
Almac Diagnostic Services’ claraT Report Assists Researchers In Uncovering New Oncology Findings
-
October 7, 2021
Dr Richard Turkington Joins Almac Diagnostic Services to Support Biomarker Research
-
January 11, 2021
Personal Genome Diagnostics and Almac Diagnostic Services Enter Strategic Collaboration to Enhance Patient Care in Oncology
-
July 21, 2020
Almac Group Announces Winners of claraT Grant Programme for Academia
-
April 24, 2020
TruSight Oncology Family Grows with Liquid Biopsy and High-Throughput Assay Additions
-
September 26, 2019
Almac’s unique gene expression report enables cancer researchers to discover exciting new insights
-
July 31, 2019
Almac Diagnostic Services Launches Sample Management Service
-
June 5, 2019
Almac Group Announces CE Mark of Diagnostic Assay to Support Turning Point Therapeutics’ Pivotal TRIDENT-1 Clinical Trial
-
May 6, 2019
Turning Point Therapeutics and Almac Diagnostic Services announce approval of an investigational device exemption for the companion diagnostic assay to the registrational TRIDENT-1 clinical study
-
April 18, 2019
Almac Group Partner with Queen’s Researchers to pioneer potentially life-changing oesophageal cancer test
-
March 27, 2019
Almac Group Launches Upgraded Version of claraT – A Unique, Software-driven Gene Expression Report
-
October 24, 2018
TP Therapeutics and Almac Diagnostic Services Enter into Agreement to Develop Next-Generation Sequencing, Pan-Cancer Companion Diagnostic
-
October 19, 2018
Almac Group Launches claraT – A Unique, Software-driven Gene Expression Report
-
October 11, 2018
Almac Group Invests in Cutting Edge Next Generation Sequencing Capabilities for Bio Pharma Clients
-
October 10, 2018
Almac Group Invests to Expand its Existing North Carolina Facility
-
April 16, 2018
Almac Diagnostic Services Validates Illumina TruSight® Tumor 170 Cancer Mutation Panel for Prospective Testing in Clinical Trials
-
February 12, 2018
Almac Diagnostic Services Partners with DNAnexus to Power Clinical Trial Assay Development
-
October 23, 2017
Queen’s University Belfast in Collaboration with Almac Group Lead Largest Study of its Kind to Transform Prostate Cancer Treatment
-
June 13, 2017
Almac Group Awarded U.S. Patents for Ground-breaking “DDRD” Assay
-
April 20, 2017
Almac Group Announces Publication of Prostate Cancer Metastatic Assay Validation
-
March 8, 2017
Almac Diagnostic Services and EORTC Establish Collaboration for Tumour Molecular Profiling
-
February 16, 2017
Almac Diagnostic Services Appoints Dr Leeona Galligan as Vice President UK Operations
-
October 10, 2016
Almac Group Discover an Exciting Link between its Immune Response Assay and Checkpoint Inhibitor Based Therapy
-
October 4, 2016
Almac Diagnostic Services Partner with ArcherDX
-
August 8, 2016
Almac Publish Second Validation of Stage II Colon Cancer Recurrence Assay in the Journal of Clinical Oncology
-
June 8, 2016
Almac Diagnostic Services Expand Companion Diagnostic Development Service Offering with NanoString Barcoding Technology
-
March 8, 2016
Almac Group Opens Additional Companion Diagnostic Laboratory in Durham NC USA
-
November 12, 2015
Almac Group to Collaborate with Illumina on Next-Generation Sequencing Based Companion Diagnostic Development
-
July 10, 2015
Almac Group Announce Companion Diagnostic Partnerships with OncoMed
-
March 3, 2015
Almac Group Appoints Dr. Shirin Khambata Ford as VP Product Development
-
February 5, 2015
Almac Appoints VP Quality and Regulatory Affairs
-
January 28, 2014
Data Presented Supporting Almac Developed Colon Signature as a Significant Predictor of Risk of Recurrence in Stage II Colon Cancer
-
January 21, 2014
Almac publishes breast cancer chemotherapy response assay in the Journal of the National Cancer Institute
-
November 26, 2013
Genomic Health and Almac Group Enter Exclusive In-Licensing Agreement to Develop and Commercialize Anthracycline Chemotherapy Benefit Test for High Risk Breast Cancer
-
September 10, 2013
Almac Offering TruSight Tumor Profiling Next-Generation Sequencing Service
-
February 1, 2012
Almac announce launch of Next Generation Sequencing (NGS) Data Analysis Services
-
November 30, 2011
Almac’s Diagnostic Laboratory Receives Accreditation from College of American Pathologists
-
November 8, 2011
Almac publishes Stage II colon cancer recurrence signature in the Journal of Clinical Oncology
-
September 7, 2011
Almac-Queen’s cancer expert to lead £4.4m collaboration
-
July 4, 2011
Almac to perform the analytic phase of AclarusDx™ for Exonhit
-
May 31, 2011
Almac data to be presented at annual ASCO meeting
-
March 30, 2011
Almac open CLIA lab for biomarker clinical trials
-
March 1, 2011
Live Webinar March 28th: An Integrated Approach to Biomarker Discovery
-
February 17, 2011
Almac announce Launch of Bioinformatics Consultancy
-
August 26, 2010
Almac Discusses New Biomarker Service on OutsourcingPharma.com
-
August 2, 2010
Almac launch Biomarkers for biopharma
-
June 28, 2010
Almac Announces Collaboration with Aeterna Zentaris to Develop Therapy and Companion Diagnostic in Cancer
-
June 3, 2010
Almac Launch Xcel Array – the Optimum Platform for Biomarker Discovery
-
April 12, 2010
Almac partners with Merck KGaA and the MRC to assess markers of response to Cetuximab therapy
-
December 1, 2009
Bioinformatics Expansion Heralds Further Growth for Almac
-
September 15, 2009
Almac and Lilly Partner on Companion Diagnostic Development
-
July 28, 2009
UM Breast Cancer Researchers partner with Almac to win prestigious Department of Defense Grant
-
July 9, 2009
Official opening of Almac Diagnostic Services headquarters
-
April 29, 2009
Dr Tanney Discusses Challenges Faced in Fine Tuning Sample Preparation Techniques
-
April 6, 2009
Almac Group Uses HP Technology to Bring New Drugs to Market Faster
-
March 10, 2009
Almac Collect Top Recognition for New Ovarian Cancer Research Product
-
January 8, 2009
Almac Selects NuGEN Ovation® Systems to Broaden Gene Expression
-
November 27, 2008
Almac addresses leading cancer specialists at All-Ireland conference
-
September 16, 2008
Almac Diagnostic Services Launches Ovarian Cancer Research Tool
-
July 31, 2008
Almac Announce World’s Largest Gene Expression Study To Develop Prognostic Test for Early Non Small Cell Lung Cancer
-
June 27, 2008
Almac Diagnostic Services Join Personalized Medicine Coalition
-
May 8, 2008
Almac Diagnostic Services in new deal to provide unique process to extract genetic information from Clinical Trial samples
-
February 26, 2008
Almac Inks 15-Year Deal with Affy to Secure Rights to Develop and Sell Array-Based Dxs
-
February 21, 2008
Almac Diagnostic Services Extends Agreement with Affymetrix
-
December 18, 2007
Almac wins top award at Tech Idol Showcase
-
November 20, 2007
BRCA1 Mutations Influence Cancer Cells’ Response to Drugs
-
August 8, 2007
Almac Diagnostic Services Announces Pioneering Genetic Research on Ductal Carcinoma In Situ (DCIS) Using Breast Cancer DSA™ Research Tool
-
May 31, 2007
Almac Diagnostic Services Attends Pre-ide Meeting With FDA for Colorectal Cancer Diagnostic Derived from FFPE Tissue Craigavon, Northern Ireland, 28 May 2007
-
April 16, 2007
Almac Diagnostic Services Announces Pioneering Genetic Research
-
December 19, 2006
Diagnostic Services Multi Year License Agreement With GeneGo
-
March 9, 2006
Eirx Therapeutic Plc & Diagnostic Services Agreement
-
January 11, 2006
Almac Diagnostic Services Receives ISO17025 Accreditation
-
January 10, 2006
ArraDx Joins Almac Sciences – Now Almac Diagnostic Services
-
August 23, 2004
Company Name Change